

St. Louis

March 30, 1965

A

P. G. Arvan
V. D. Dunlap
R. R. Rumer

PLAINTIFF'S
EXHIBIT
P-0419

FILE	<input checked="" type="checkbox"/>
D-11	<input type="checkbox"/>
JTS	<input type="checkbox"/>
V-14	<input checked="" type="checkbox"/>
M-11	<input checked="" type="checkbox"/>
R-11	<input checked="" type="checkbox"/>
R-11	<input checked="" type="checkbox"/>
EP-11	<input checked="" type="checkbox"/>

Mr. Paul Hoffman

I talked with the Hercules representative who attended the Dow meeting on the 2,4,5-T problem. He was Dr. Jack Frawley, a toxicologist.

It appears the presentation was the same as the one you and I were given. Representatives of Diamond and Hooker were there. Dr. Frawley stated that Dow told the various companies in private what the content of dioxane was in their 2,4,5-T acid. I gathered that Diamond and Hooker had some but Hercules stated they were told they had none.

It appeared to Frawley that Dow was having this meeting because they did not think they could, in conscience, not tell industry about their findings. Hercules also seems to believe that the Public Health Service would be very happy to get into the act, whether or not the chloracne exists in the ultimate user. I must agree with them about this and it would seem almost mandatory that we see if we can first firm up our analytical methods and then devise ways to minimize the presence of this known chloracne agent.

There is also another very good reason for us to do this. Regardless of what we think of the rabbit test, this dioxane compound must be a potent contaminant. Very conceivably, it can be a potent carcinogen. We, therefore, will never know how close we are to having another epidemic at Nitro, and we certainly don't want to go through that again.

I am going to be out of the country until about April 20, but Dr. Johnson and Mr. Wheeler are quite familiar with the various aspects of this problem and are available for discussions.

R. Ernest Kelly, M. D.

REK/ln

72754